Research graph
References from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Tracking the evolution of non-small-cell lung cancer
10.1056/nejmoa1616288 · 2017 · External reference
Clonal heterogeneity and tumor evolution: past, present, and the future
10.1016/j.cell.2017.01.018 · 2017 · External reference
Intratumor heterogeneity: the Rosetta stone of therapy resistance
10.1016/j.ccell.2020.03.007 · 2020 · External reference
The evolution of lung cancer and impact of subclonal selection in TRACERx
10.1038/s41586-023-05783-5 · 2023 · External reference
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
10.1056/nejmoa1113205 · 2012 · External reference
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
10.1126/science.aaf1490 · 2016 · External reference
Heterogeneity of the tumor immune microenvironment and its clinical relevance
10.1186/s40164-022-00277-y · 2022 · External reference
Cancer immune evasion, immunoediting and intratumour heterogeneity
10.1038/s41577-024-01111-8 · 2025 · External reference
The role of tumor heterogeneity in immune-tumor interactions
10.1007/s10555-021-09957-3 · 2021 · External reference
Co-evolution of tumor cells and their microenvironment
10.1016/j.tig.2008.10.012 · 2009 · External reference
The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth
10.1016/j.ccell.2023.02.016 · 2023 · External reference
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
10.1126/science.1203486 · 2011 · External reference
Cancer immunoediting in the era of immuno-oncology
10.1158/1078-0432.ccr-21-1804 · 2022 · External reference
Therapeutic applications of the cancer immunoediting hypothesis
10.1016/j.semcancer.2021.03.002 · 2022 · External reference
Cancer immunoediting and resistance to T cell-based immunotherapy
10.1038/s41571-018-0142-8 · 2019 · External reference
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
10.1038/nature10755 · 2012 · External reference
Expression of tumour-specific antigens underlies cancer immunoediting
10.1038/nature10803 · 2012 · External reference
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
10.1056/nejmoa1801005 · 2018 · External reference
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
10.1016/s1470-2045(20)30641-0 · 2021 · External reference
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
10.1056/nejmoa1606774 · 2016 · External reference
Perioperative pembrolizumab for early-stage non-small-cell lung cancer
10.1056/nejmoa2302983 · 2023 · External reference
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
10.1056/nejmoa2202170 · 2022 · External reference
Perioperative nivolumab in resectable lung cancer
10.1056/nejmoa2311926 · 2024 · External reference
Perioperative durvalumab for resectable non-small-cell lung cancer
10.1056/nejmoa2304875 · 2023 · External reference
Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee
10.1016/j.jtho.2022.09.109 · 2022 · External reference
The challenges of tumor mutational burden as an immunotherapy biomarker
10.1016/j.ccell.2020.10.001 · 2021 · External reference
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
10.1016/j.annonc.2020.08.2105 · 2020 · External reference
KEAP1 and TP53 frame genomic, evolutionary, and immunologic subtypes of lung adenocarcinoma with different sensitivity to immunotherapy
10.1016/j.jtho.2021.08.010 · 2021 · External reference
Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
10.1016/j.jtho.2021.10.013 · 2022 · External reference
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
10.1016/j.annonc.2022.12.002 · 2023 · External reference
Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy
10.1158/1078-0432.ccr-24-0626 · 2024 · External reference
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
10.1038/s41467-020-20171-7 · 2021 · External reference
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
10.1038/s41467-018-07767-w · 2018 · External reference
Analysis of immune intratumor heterogeneity highlights immunoregulatory and coinhibitory lymphocytes as hallmarks of recurrence in stage I non-small cell lung cancer
10.1016/j.modpat.2022.100028 · 2023 · External reference
Neoantigen-directed immune escape in lung cancer evolution
10.1038/s41586-019-1032-7 · 2019 · External reference
Spatial multiomics reveals intratumoral immune heterogeneity with distinct cytokine networks in lung cancer brain metastases
10.1158/2767-9764.crc-24-0201 · 2024 · External reference
Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer
10.1016/j.ccell.2025.01.012 · 2025 · External reference
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
10.1002/path.6165 · 2023 · External reference
Genomic-transcriptomic evolution in lung cancer and metastasis
10.1038/s41586-023-05706-4 · 2023 · External reference
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
10.1038/s41588-023-01355-5 · 2023 · External reference
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
10.1016/s0140-6736(16)00587-0 · 2016 · External reference
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
10.1016/s0140-6736(16)32517-x · 2017 · External reference
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
10.1016/j.ccell.2022.02.002 · 2022 · External reference
Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types
10.1038/s41467-024-48310-4 · 2024 · External reference
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
10.1016/j.ccell.2021.04.014 · 2021 · External reference
Deciphering resistance mechanisms in cancer: MATCH-R study
10.1186/s12943-024-02134-4 · 2024 · External reference
Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images
10.1016/j.celrep.2018.03.086 · 2018 · External reference
AI driven assessment of lung cancer microenvironment composition
10.1016/j.jpi.2024.100400 · 2024 · External reference
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
10.1158/2159-8290.cd-12-0095 · 2012 · External reference
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
10.1126/scisignal.2004088 · 2013 · External reference
Comprehensive molecular profiling of lung adenocarcinoma
10.1038/nature13385 · 2014 · External reference
Comprehensive genomic characterization of squamous cell lung cancers
10.1038/nature11404 · 2012 · External reference
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
10.1186/s40164-021-00211-8 · 2021 · External reference
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
10.1038/s41571-021-00520-1 · 2021 · External reference
Programmed Death-Ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC
10.1016/j.jtho.2020.04.026 · 2020 · External reference
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · 2015 · External reference
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50
10.1016/j.esmoop.2025.105897 · 2025 · External reference
Immunotherapy or chemoimmunotherapy in older adults with advanced non–small cell lung cancer
10.1001/jamaoncol.2023.6277 · 2024 · External reference
Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer
10.1007/s12094-023-03360-w · 2024 · External reference
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
10.1016/s0140-6736(23)00774-2 · 2023 · External reference
